Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products / Molecular and specialised diagnostics / Hospital laboratory routine molecular infectious-disease testing
Hospital laboratory routine molecular infectious-disease testing
Molecular assays (respiratory, GI, bloodstream, meningitis panels and single-target PCR) run in hospital and clinical laboratories to support routine inpatient and outpatient diagnosis of common infectious disease. Job to be done: deliver a validated, high-throughput, low-cost-per-result molecular answer for patients already in the care pathway. Excludes rapid/point-of-care results returned in under ~30 minutes (separate niche) and complex genomic interpretation work (separate niche).
- Level
- Niche
- Segmented by
- Customer type
- Buyers
- Hospital and clinical laboratories (public and private hospital systems, integrated lab networks)
- Buying centre
- Centralised hospital laboratory procurement and capital equipment committee, with input from microbiology/lab medicine leadership, infection control, and hospital finance; multi-year framework agreements with reagent rental or instrument-placement terms.
- Respiratory and sepsis season volumes and outbreak-driven testing demand
- Replacement or expansion of installed PCR/automated molecular platforms
- Hospital cost-reduction and lab-consolidation programmes
- Reimbursement and tender cycles for panel-based syndromic testing
- Per-test cost and consumable spend pressure under fixed DRG/reimbursement budgets
- Instrument capital spending caution and instrument-placement terms that lock in reagent volumes
- Fragmented legacy platform estates and open-reagent versus closed-cartridge trade-offs
- Menu breadth needed to cover respiratory, GI and bloodstream panels without excessive capital
How this was sized
$8.8B ($6.9B–$10.7B) · 2025 · Triangulated
Pool triangulation: published 2025 clinical diagnostics revenue estimates of USD 81.74B [10], USD 86.5B [9], USD 92.37B [1], USD 110.85B [8], USD 115.4B [6] and USD 118.60B [3] give a mid-point of ~USD 100B. Molecular and specialised diagnostics assumed at 22% of that pool (immunodiagnostics alone is 28.2% of laboratory diagnostics [8], with molecular the next-largest technology block) = USD 22.0B submarket. Routine infectious-disease molecular assumed 40% of the submarket = USD 8.8B (range 6.9-10.7B). Forecast: 8,800 x 1.07^5 = USD 12,340M in 2030; 7.0% CAGR sits above the 4.78% clinical diagnostics CAGR [1] and near the 6.6% diagnostic tests CAGR [3], reflecting molecular mix gain. Low confidence: both the 22% share and the 40% allocation are assumptions, not published figures.
- Clinical Diagnostics Market Size, Share, Growth and Forecast, 2025-2035
credenceresearch.com · 2026-10-15 - Global Diagnostic Tests Market Size, Share, Trends and Forecast 2026-2033
pheonixresearch.com · 2026-07-16 - Worldwide Clinical Diagnostics Market 2026 – PW Consulting
pmarketresearch.com · 2026-06-16 - Clinical Diagnostics Market | Clarivant Health
clarivanthealth.com - Laboratory Diagnostics Market 2026 – PW Consulting
pmarketresearch.com · 2026-06-02 - Clinical Diagnostics Market Growth & Forecast 2026-2036
futuremarketinsights.com · 2026-11-02 - Clinical Diagnostics Market Size, Share, Growth Report 2026-2030
thebusinessresearchcompany.com · 2026-09-14
Alongside it in Molecular and specialised diagnostics
// Sell into Hospital laboratory routine molecular infectious-disease testing